Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Point-of-care testing and home testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound

Research output: Contribution to journalReviewpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{42914899578244f6b70116212238116f,
title = "Point-of-care testing and home testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound",
abstract = "Breaking through the biologic therapy efficacy plateau for inflammatory bowel disease requires the strategic development of personalized biomarkers in the tight control model. After risk stratification early in the disease course, targeted serial monitoring consistently to assess clinical outcomes in response to therapy allows for quick therapeutic adjustments before bowel damage can occur. Point-of-care intestinal ultrasound performed by the treating gastroenterologist is an accurate cross-sectional biomarker that monitors intestinal inflammation in real-time, enhances patient care, and increases shared understanding to help achieve common treatment goals. Combining intestinal ultrasound during a clinic visit with existing serum and stool biomarkers in a home testing setup with electronic health monitoring allows for an optimized, patient-centered personalized treatment algorithm that may improve treatment outcomes. Here, we review the current state, pragmatic considerations, and future implications of point-of-care testing and home testing for non-invasive inflammatory bowel disease monitoring in the tight control model.",
keywords = "Colitis, Ulcerative/metabolism, Crohn Disease/metabolism, Humans, Inflammatory Bowel Diseases/diagnostic imaging, Point-of-Care Testing, Ultrasonography, Biomarker, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease, eHealth",
author = "Rune Wilkens and Michael Dolinger and Johan Burisch and Christian Maaser",
note = "Copyright {\textcopyright} 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.",
year = "2022",
month = apr,
doi = "10.1053/j.gastro.2021.10.052",
language = "English",
volume = "162",
pages = "1476--1492",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B./Saunders Co",
number = "5",

}

RIS

TY - JOUR

T1 - Point-of-care testing and home testing

T2 - Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound

AU - Wilkens, Rune

AU - Dolinger, Michael

AU - Burisch, Johan

AU - Maaser, Christian

N1 - Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

PY - 2022/4

Y1 - 2022/4

N2 - Breaking through the biologic therapy efficacy plateau for inflammatory bowel disease requires the strategic development of personalized biomarkers in the tight control model. After risk stratification early in the disease course, targeted serial monitoring consistently to assess clinical outcomes in response to therapy allows for quick therapeutic adjustments before bowel damage can occur. Point-of-care intestinal ultrasound performed by the treating gastroenterologist is an accurate cross-sectional biomarker that monitors intestinal inflammation in real-time, enhances patient care, and increases shared understanding to help achieve common treatment goals. Combining intestinal ultrasound during a clinic visit with existing serum and stool biomarkers in a home testing setup with electronic health monitoring allows for an optimized, patient-centered personalized treatment algorithm that may improve treatment outcomes. Here, we review the current state, pragmatic considerations, and future implications of point-of-care testing and home testing for non-invasive inflammatory bowel disease monitoring in the tight control model.

AB - Breaking through the biologic therapy efficacy plateau for inflammatory bowel disease requires the strategic development of personalized biomarkers in the tight control model. After risk stratification early in the disease course, targeted serial monitoring consistently to assess clinical outcomes in response to therapy allows for quick therapeutic adjustments before bowel damage can occur. Point-of-care intestinal ultrasound performed by the treating gastroenterologist is an accurate cross-sectional biomarker that monitors intestinal inflammation in real-time, enhances patient care, and increases shared understanding to help achieve common treatment goals. Combining intestinal ultrasound during a clinic visit with existing serum and stool biomarkers in a home testing setup with electronic health monitoring allows for an optimized, patient-centered personalized treatment algorithm that may improve treatment outcomes. Here, we review the current state, pragmatic considerations, and future implications of point-of-care testing and home testing for non-invasive inflammatory bowel disease monitoring in the tight control model.

KW - Colitis, Ulcerative/metabolism

KW - Crohn Disease/metabolism

KW - Humans

KW - Inflammatory Bowel Diseases/diagnostic imaging

KW - Point-of-Care Testing

KW - Ultrasonography

KW - Biomarker

KW - Crohn's Disease

KW - Ulcerative Colitis

KW - Inflammatory Bowel Disease

KW - eHealth

UR - http://www.scopus.com/inward/record.url?scp=85127239416&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2021.10.052

DO - 10.1053/j.gastro.2021.10.052

M3 - Review

C2 - 34995530

VL - 162

SP - 1476

EP - 1492

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -

ID: 70586299